<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03270709</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00094833</org_study_id>
    <nct_id>NCT03270709</nct_id>
  </id_info>
  <brief_title>Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV</brief_title>
  <official_title>Effect of High-Dose Vitamin D3 on Alveolar Macrophage Function, LL-37, and Oxidative Stress in Smokers and Non-Smokers With and Without HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Supplementation with vitamin D improves HIV+ macrophages phagocytosis in vitro. There is&#xD;
      evidence to suggest that administering vitamin D can in fact improve immune function in&#xD;
      individuals. The study will evaluate the impact of high dose vitamin D in HIV+ smokers' and&#xD;
      HIV- smokers' in vivo. The primary goal is to improve innate immune host response to&#xD;
      infection in patients already at high risk by virtue of HIV and smoking status.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tobacco smoke suppresses the lung's ability to fight infection. Smoking is three times more&#xD;
      prevalent in the HIV+ compared to HIV- patients. Viral load was found to be significantly&#xD;
      increased in HIV+ smokers compared to HIV+ non-smokers, suggesting that smoking enhances&#xD;
      HIV-1 viral replication in macrophages, which contributes to disease progression. Vitamin D&#xD;
      deficiency has been associated with increased mortality in HIV+ persons, but there is limited&#xD;
      research on how this is impacting the health of these highest risk patients and if aggressive&#xD;
      repletion with vitamin D can improve overall health.The study team hypothesizes that vitamin&#xD;
      D administration will increase pathogen clearance and improve innate immune function.&#xD;
&#xD;
      The proposed pre and post interventional study is designed to characterize alveolar&#xD;
      macrophage function and lung immunity according to tobacco use and HIV status, and determine&#xD;
      the impact of high dose oral vitamin D3 on AM phagocytic function and innate immunity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated early due to lack of funding and the COVID-19 pandemic.&#xD;
  </why_stopped>
  <start_date type="Actual">April 11, 2018</start_date>
  <completion_date type="Actual">October 15, 2018</completion_date>
  <primary_completion_date type="Actual">October 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A total of 44 subjects (11 per group, smokers and non-smokers, HIV+, HIV-) will be enrolled.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in alveolar macrophage (AM) phagocytic index between HIV+ smokers compared to HIV- non-smokers.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration.</time_frame>
    <description>A phagocytic index will be determined by challenging AM isolated from bronchoalveolar lavage (BAL) to Staph. Aureus in vitro.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in phagocytosis percent positive between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration.</time_frame>
    <description>Difference in phagocytosis percent positive between HIV+ smokers compared to HIV- non-smokers will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in alveolar macrophage (AM) phagocytic index before and after vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration</time_frame>
    <description>A phagocytic index will be determined by challenging AM isolated from bronchoalveolar lavage (BAL) to Staph. Aureus in vitro.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in total and free vitamin D (25(OH) D) between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration.</time_frame>
    <description>Difference in total and free 25(OH) D between HIV+ smokers compared to HIV- non-smokers will be measure by ELISA (enzyme-linked immunosorbent assay) levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in peptide LL-37 between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration.</time_frame>
    <description>Difference in an antimicrobial and immunostimulating/-modulating peptide LL-37 between HIV+ smokers compared to HIV- non-smokers will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in tumor necrosis factor alpha (TNF-α) between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration.</time_frame>
    <description>Difference in tumor necrosis factor alpha (TNF-α) - cytokine involved in systemic inflammation - between HIV+ smokers compared to HIV- non-smokers will be calculated .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in messenger ribonucleic acid (mRNA) expression of LL-37 between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration.</time_frame>
    <description>Difference in mRNA expression of antimicrobial peptide LL-37 between HIV+ smokers compared to HIV- non-smokers will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in alveolar oxidative stress between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration.</time_frame>
    <description>Difference in alveolar oxidative stress between HIV+ smokers compared to HIV- non-smokers will be measured using AM isolated from bronchoalveolar lavage (BAL) .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in total and free vitamin D (25(OH) D) before and after vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration</time_frame>
    <description>Difference in total and free vitamin D (25(OH) D) will be measure by ELISA (enzyme-linked immunosorbent assay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in peptide LL-37 before and after vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration</time_frame>
    <description>Difference in peptide LL-37 levels will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in tumor necrosis factor alpha (TNF-α) before and after vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration</time_frame>
    <description>Difference in tumor necrosis factor alpha (TNF-α) will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in mRNA expression of LL-37 before and after vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration</time_frame>
    <description>Difference in mRNA expression of LL-37 will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in alveolar oxidative stress before and after vitamin D administration.</measure>
    <time_frame>Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration</time_frame>
    <description>Difference in alveolar oxidative stress will be measured using AM isolated from bronchoalveolar lavage (BAL) .</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Vitamin D Deficiency</condition>
  <condition>Smoker Lung</condition>
  <arm_group>
    <arm_group_label>HIV+ smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 450,000 IU orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV- non-smokers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 450,000 IU orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV+ non-smokers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 450,000 IU orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV- smokers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin D3 450,000 IU orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3 450,000 IU orally</intervention_name>
    <description>Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.</description>
    <arm_group_label>HIV+ non-smokers</arm_group_label>
    <arm_group_label>HIV+ smokers</arm_group_label>
    <arm_group_label>HIV- non-smokers</arm_group_label>
    <arm_group_label>HIV- smokers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects living with HIV-1 infection who have been on anti-retroviral therapy (ART)&#xD;
             for a minimum of 12 months and are followed longitudinally for their HIV healthcare;&#xD;
&#xD;
          -  Ability to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 yrs old;&#xD;
&#xD;
          -  Known or possible pregnancy or breastfeeding;&#xD;
&#xD;
          -  Documented history of cirrhosis or a direct bilirubin ≥ 2.0 mg/dL;&#xD;
&#xD;
          -  Documentation of left ventricular ejection fraction &lt; 40% or myocardial infarction&#xD;
             within the past 6 months;&#xD;
&#xD;
          -  End-stage renal disease requiring dialysis or a serum creatinine ≥ 2 mg/d;&#xD;
&#xD;
          -  Spirometry with forced vital capacity (FVC) or forced expiratory volume (FEV1)&lt; 70% of&#xD;
             predicted value;&#xD;
&#xD;
          -  Bleeding disorders such as thrombocytopenia or significant gastrointestinal bleeding&#xD;
             within the past year;&#xD;
&#xD;
          -  Inability to undergo bronchoscopy safely;&#xD;
&#xD;
          -  High risk behaviors without known HIV status.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny E Han, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Atlanta VA Medical center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Health System (non-CRN), Grady Health System (CRN), Ponce Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 31, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2017</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Jenny Elizabeth Han</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Vitamin D3</keyword>
  <keyword>Pulmonary disease</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>HIV</keyword>
  <keyword>Smoking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

